In a real-world evidence study, the 14-day Tegoprazan-based triple therapy demonstrated a higher rate of Helicobacter pylori (H. pylori) eradication and acceptable side effects as compared to 7-day Tegoprazan-based triple therapy. Yoon Suk Jung et al. sought to determine the effect of treatment duration (7 vs. 14 days) on the elimination of H. pylori using Potassium-competitive acid blockers (P-CAB)-based triple therapy.

A retrospective analysis was done on the data of patients who underwent Tegoprazan-based triple therapy (50 mg Tegoprazan + 1000 mg Amoxicillin + 500 mg Clarithromycin 2 times a day for one or two weeks) as a first-line intervention for H. pylori infection. In the intention-to-treat (ITT) study, eradication rate served as major outcome.

Notably, 435/948 and 513/948 participants were administered Tegoprazan-based triple treatment (7-day and 14-day regimens, respectively). In the 14-day therapy group, the rate of elimination was greater than in the 7-day therapy group, as shown in Table 1:

The overall rate of adverse events was same in both groups. As found, 6 patients in the 14-day therapy group stopped taking their prescription drugs because of side effects. Four patients (67%) discontinued medicines within 4 days. When Tegoprazan-based triple therapy is utilized to treat H. pylori infection in areas with significant Clarithromycin resistance, a 14-day treatment schedule may be necessary.